Company: CERO
Filing Date: 2025-05-07
Form Type: DEF 14A
Source: 0001213900-25-040263
Chunk: 90

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-07
Form: DEF 14A
Chunk 90
---
     |   2,659 |
| Brian G. Atwood, Former Chief Executive Officer and Chairman(2) |     |   5,080 |
| Charles R. Carter, Former Chief Financial Officer(3)            |     |       — |
| Daniel Corey, M.D., Former Chief Technology Officer(4)          |     |       — |

____________ (1)Excludes 5,272 options granted under the 2024 Plan which were forfeited on September 30, 2024. (2)Excludes 13,318 options granted under the 2024 Plan which were forfeited on September 30, 2024. (3)Excludes 4,954 options granted under the 2024 Plan which were forfeited on September 30, 2024. (4)Excludes 4,613 options granted under the 2024 Plan which were forfeited on September 23, 2024. Equity Grant Timing Our compensation committee has generally granted equity awards on an annual basis and when it has determined necessary or appropriate for retention and recruitment, including following the successful completion of major corporate transactions or regulatory milestones.In addition, eligible employees, including our NEOs, may voluntarily enroll in our 2024 Employee Stock Purchase Plan, or ESPP, and receive an option to purchase shares at a discount using payroll deductions accumulated during the prior six months. No shares were issued under the ESPP during 2024. During 2024, our compensation committee did not take into account any material nonpublic information when determining the timing and terms of equity incentive awards, and we did not timethe disclosure of material nonpublic information for the purpose of affecting the value of executive compensation. During 2024, we did not grant stock options to our named executive officers during any period beginning four business days before and ending one business day after the filing or furnishing of a Form 10 -Q, 10 -Kor 8 -Kthat discloses material nonpublic information. Stock Option Awards The Compensation Committee approved stock option awards to each of the then -servingexecutive officers in March 2024 following the completion of the Business Combination. In light of the decline in the Company’s stock price and financial condition, resulting in challenges with executive and employee retention, the extraordinary efforts required of the Company’s management team in connection with obtaining financing to remain viable and to cause the FDA to lift the clinical hold implemented in July 2024 and accept the submission of the IND in November 2024